Novartis divests Sandoz's US generics businesses to Aurobindo for up to $1bn; deal later terminated
Aurobindo Pharma Ltd.'s Aurobindo Pharma USA Inc. agreed to buy certain portions of Sandoz International GMBH's US Sandoz's US generic dermatology and US generic oral solids businesses, which parent Novartis AG is divesting.
- Generic Drugs
- Topical Delivery
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.